Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma

24 Oct 2019

Abstract excerpt

In multiple myeloma the mutational profile is mainly represented by translocations involving chromosome 14 and by single nucleotide mutations, frequently involving genes implicated in the mitogen activated protein kinase (MAPK) pathway, as KRAS, NRAS, and, less frequently, BRAF. Because KRAS/NRAS/BRAF mutations are associated with a higher number of mutations per patient, we hypothesize that this group of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Melanoma and MAPK Pathways
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31709194
DOI: 10.3389/fonc.2019.01137

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple MyelomaPMID 31709194Read ↗

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activationSemantic proximity Read ↗

Plasma cell myeloma with RAS/BRAF mutations: Clinicopathologic, molecular genetic features and outcomes of 68 patientsSemantic proximity Read ↗

RAS mutations - for better or for worse in multiple myeloma?Semantic proximity Read ↗

Pathway-Directed Therapy in Multiple MyelomaSemantic proximity Read ↗

Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis.Semantic proximity Read ↗

New Targets and New Agents in High-Risk Multiple Myeloma.Semantic proximity Read ↗

[Abnormalities of signal transduction molecules in multiple myeloma].Semantic proximity Read ↗

Targeting BRAF in multiple myeloma.Semantic proximity Read ↗

Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.Semantic proximity Read ↗

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.Semantic proximity Read ↗

Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma.Semantic proximity Read ↗

Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.